Rein Therapeutics

Yahoo Finance • 4 months ago

Rein Therapeutics Receives FDA Clearance to Resume U.S. Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis

FDA lifts clinical hold following review of Company’s Complete Response submission.Company expects to restart U.S. enrollment in late 2025 or early 2026 across 20 clinical sites.Early data suggests that LTI-03 may not only slow fibrosis bu... Full story

Yahoo Finance • 5 months ago

Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis

EMA approval covers study sites in Germany and Poland as part of the Company’s global Phase 2 RENEW trialTrial will evaluate LTI-03, a first-in-class therapy designed to both reduce lung scarring and promote repair AUSTIN, Texas, Oct. 09... Full story

Yahoo Finance • 6 months ago

Rein Therapeutics Announces Publication of New Translational Data in iScience on Company’s Novel Therapy for Idiopathic Pulmonary Fibrosis

AUSTIN, Texas, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonar... Full story

Yahoo Finance • 6 months ago

Rein Therapeutics files to sell 10M shares of common stock for holders

* Rein Therapeutics (NASDAQ:RNTX [https://seekingalpha.com/symbol/RNTX]) filed to sell 10M shares of common stock for holders. * Filing [https://seekingalpha.com/filing/10383745] MORE ON AILERON THERAPEUTICS * Rein Therapeutics... Full story

Yahoo Finance • 7 months ago

UK regulator approves Rein Therapeutics' phase 2 trial for IPF drug

LONDON - Rein Therapeutics (NASDAQ:RNTX), a clinical-stage biotech company currently valued at $26 million, announced Tuesday that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has authorized the initiation of its Phase... Full story

Yahoo Finance • 7 months ago

Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis

AUSTIN, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fi... Full story

Yahoo Finance • 7 months ago

Rein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025

AUSTIN, Texas, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary... Full story